All In Biotech

Free tool

FAERS Monitor: Rimso-50

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 017788 or its brand name (Rimso-50, Dimethyl Sulfoxide). Reports on generic versions are filed under their own applications.

Reports

243

Serious

198

81% of reports

Hospitalization

82

Death reported

31

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective49
  • headache48
  • nausea48
  • off label use42
  • abdominal pain41
  • pain39
  • pyrexia39
  • dyspepsia28
  • fatigue28
  • constipation27
  • infusion related reaction27
  • malaise27
  • weight decreased26
  • anaemia25
  • erythema25

Reports by year received

View as table
YearReports
20044
20056
20062
20072
20085
200912
20104
201110
20123
20131
20143
201515
20164
201719
201814
201921
202016
202118
202221
202328
202410
202515
202610

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,916 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
infusion related reactionSignal2735.324.7867
dyspepsiaSignal2824.617.4614
abdominal painSignal4115.311.5538
anaemiaSignal2511.37.8228
constipationSignal2710.77.5231
erythemaSignal2510.57.3208
pyrexiaSignal399.87.3303
weight decreasedSignal268.15.6156
headacheSignal486.65.1231
painSignal395.54.1143
malaiseSignal275.33.793
nauseaSignal485.24.1167
off label useSignal424.23.2102
drug ineffectiveSignal493.22.578
fatigueSignal283.12.240

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.